DCVAC

Active substance
DCVAC
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Prostate cancer
Extended indication
Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

1. Product

Manufacturer
Sotio
Mechanism of action
Immunostimulation
Route of administration
Intravenous
Therapeutical formulation
Intravenous drip
Budgetting framework
Intermural (MSZ)
Additional comments
Immunostimulants

2. Registration

Registration route
Centralised (EMA)
Submission date
2020
Expected Registration
2021
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Dit geneesmiddel is geclassificeerd als een ATMP.

3. Therapeutic value

Therapeutic value
No judgement
Duration of treatment
Not found
References
NCT02111577

4. Expected patient volume per year

References
NKR; GIPdatabank
Additional comments
2.302 diagnoses prostaatkanker stadium 4 in 2015. 75% van deze patiënten ontwikkelt CRCP (n=1.727). In 2015 werden 1.648 patiënten voor deze indicatie behandeld met enzalutamide. Een deel van deze patienten zal in aanmerking komen voor deze behandeling.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
Yes
Indication extensions
prostate cancer at various stages
References
https://www.sotio.com/pipeline/dcvac-product-candidates

9. Other information

There is currently no futher information available.